Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.39 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.37 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.37 |
| ▸ | KLK7 | P49862 | 1/20 | 0.37 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.37 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17541276 | 0.94 | PTPN1 (0.38) | MDM2SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL17550383 | 0.94 | PTPN1 (0.38) | MDM2SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL31726486 | 0.93 | PTPN1 (0.37) | MDM2SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL17541309 | 0.92 | KLK7 (0.38) | MDM2SIRT2SIRT1SIRT3PSMB8 | |
| SCHEMBL2734925 | 0.90 | HTR2A (0.40) | SIRT2SIRT1SIRT3HTR2ASIRT5 | |
| SCHEMBL12094377 | 0.90 | HTR2A (0.40) | SIRT2SIRT1SIRT3HTR2ASIRT5 | |
| SCHEMBL12944195 | 0.90 | HTR2A (0.40) | SIRT2SIRT1SIRT3HTR2ASIRT5 | |
| SCHEMBL19731720 | 0.90 | HTR2A (0.40) | SIRT2SIRT1SIRT3HTR2ASIRT5 | |
| SCHEMBL13830646 | 0.90 | HTR2A (0.40) | SIRT2SIRT1SIRT3HTR2ASIRT5 | |
| SCHEMBL29579452 | 0.90 | HTR2A (0.40) | SIRT2SIRT1SIRT3HTR2ASIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3972649-B1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| US-20240042051-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | LES LABORATOIRES SERVIER (FR) | 2024-02-08 | — | — | US | disclosed |
| EP-4251208-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2023-10-04 | — | — | EP | disclosed |
| US-20230092679-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-03-23 | — | — | US | disclosed |
| US-20230081720-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-03-16 | — | — | US | disclosed |
| WO-2022115451-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| EP-3972651-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| EP-3972649-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230092679-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MCL1, BCL9, BAK1 | MDM2 528/4885SIRT2 2468/4885SIRT1 1706/4885 |
| US-20230081720-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MCL1, CD74, CD99 | MDM2 533/4885SIRT2 3411/4885SIRT1 3424/4885 |
| US-20240042051-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MCL1, CD58, LENG8 | MDM2 1619/4885SIRT2 3246/4885SIRT1 3214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.